Sponsor introductory remarks on measure. (CR H535-536)
This bill amends the Social Security Act to expand and clarify the orphan-drug exclusion from the Drug Price Negotiation Program. It directs the Secretary not to count periods when a product held orphan status when calculating elapsed time since approval, and changes language so an orphan designation may cover one or more rare diseases or conditions.
Progressives emphasize higher Medicare costs and weakened negotiation leverage
Relative to its intended legislative type, this bill is a focused substantive amendment to the Social Security Act that clarifies and expands the orphan-drug exclusion for the Drug Price Negotiation Program.
This bill amends the Social Security Act to expand and clarify the orphan-drug exclusion from the Drug Price Negotiation Program.
It directs the Secretary not to count periods when a product held orphan status when calculating elapsed time since approval, and changes language so an orphan designation may cover one or more rare diseases or conditions.
Technically narrow and administrable, likely backed by industry; contested on drug‑price grounds and lacks compromise features, lowering enactment odds.
Relative to its intended legislative type, this bill is a focused substantive amendment to the Social Security Act that clarifies and expands the orphan-drug exclusion for the Drug Price Negotiation Program. The statutory edits are specific and integrate with existing law, but the bill omits common implementation adjuncts such as an effective date, fiscal impact acknowledgement, and oversight or reporting requirements.
Progressives emphasize higher Medicare costs and weakened negotiation leverage
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize higher Medicare costs and weakened negotiation leverage
Likely skeptical.
While valuing incentives for rare-disease research, this persona will worry the change broadly expands exclusions and weakens Medicare's drug-price negotiation leverage.
They would seek safeguards to prevent industry gaming and protect federal spending and patient affordability.
Mixed and pragmatic.
Sees merit in protecting incentives and clarifying law, but is concerned about fiscal impact and potential loopholes.
Would favor limited, targeted language, transparency, and oversight to balance innovation incentives with cost containment.
Supportive.
Views the bill as protecting incentives for biomedical innovation and limiting federal interference in pricing decisions.
Sees clarification as pro-innovation and pro-patient, reducing regulatory uncertainty for drug developers.
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Still ahead
Technically narrow and administrable, likely backed by industry; contested on drug‑price grounds and lacks compromise features, lowering enactment odds.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize higher Medicare costs and weakened negotiation leverage
Technically narrow and administrable, likely backed by industry; contested on drug‑price grounds and lacks compromise features, lowering en…
Relative to its intended legislative type, this bill is a focused substantive amendment to the Social Security Act that clarifies and expands the orphan-drug exclusion for the Drug Price Negotiation Program. The statuto…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.